IP Library Granted Patent US 7,935,770
Granted Patent B2
US 7,935,770 · App. 11/772,939 · Granted May 3, 2011

Surface active prepolymers with both fluorine-containing groups and hydrophilic groups

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,935,770
App. No.
11/772,939
Filed
Jul 3, 2007
Granted
May 3, 2011
Kind
B2
Art Unit
1762
USPC
526/243
Abstract

Provided are surface modified contact lenses formed from one or more fumaric- or itaconic-containing prepolymers having polymerizable functionality that is complimentary to polymerizable hydrophilic polymers.

Claims (12)

1. A hydrogel comprising a polymerized monomer mix of a polymerizable monomer mixture comprising at least one prepolymer of the following structure:

YCO—CH═CHCOXOCCH═CH—COY  (I)

and

CH 2 ═C(CH 2 COY)—COXOC(CH 2 COY)C═CH 2   (II)

wherein Y is a group derived from a reactive oligomer of hydrophilic monomers and X is derived from a reactive fluoroether.

2. A medical device comprising the hydrogel of claim 1 .

3. The medical device of claim 2 wherein the medical device has at least one of the properties selected from the group consisting of oxygen permeable, hydrolytically stable, biologically inert, and transparent.

4. The medical device of claim 2 wherein the medical device is polymerized to form three-dimensional networks which permit the transport of oxygen.

5. The medical device of claim 2 wherein the medical device is polymerized to form an optically clear, strong and hydrophilic medical device.

6. The medical device of claim 2 wherein the medical device is an ophthalmic lens.

7. The medical device of claim 6 wherein the medical device is a contact lens.

8. The medical device of claim 2 wherein the medical device is an intraocular lens.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →